beta blockers and glp-1 Glucagon-like peptide-1 receptor: mechanisms advances in therapy Mapping the effectiveness and risks
Description
WARNING THIS PRODUCT IS ONLY IN
This innovation addresses a long-standing barrier in obesity care: the reliance on injectable therapies
The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia
Diabetes itself, however, comes with its own risk of blindness, namely diabetic retinopathy
A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists medications that are widely prescribed for metabolic disease have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.
